Is Phaxiam Therapeutics SA halal to invest in?

According to Musaffa's Shariah screening methodology, Phaxiam Therapeutics SA (PHXM.PA) is currently classified as NOT HALAL as of September 2024. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Phaxiam Therapeutics SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Phaxiam Therapeutics SA using these criteria to determine its compliance status.

Can Muslims buy shares of Phaxiam Therapeutics SA?

Muslim investors may consider investing in Phaxiam Therapeutics SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Phaxiam Therapeutics SA classified as NOT HALAL?

Musaffa determines the Shariah status of Phaxiam Therapeutics SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Phaxiam Therapeutics SA updated?

The Shariah compliance status of Phaxiam Therapeutics SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Phaxiam Therapeutics SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Phaxiam Therapeutics SA?

You can check the latest Shariah compliance status of Phaxiam Therapeutics SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Phaxiam Therapeutics SA PHXM.PA

€0.10 €0.00 (1.95%) 1D

Last Updated: Jun 17, 12:00 AM·XPAR

PHXM.PA Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: September 13, 2024

Report Source: 2023 Annual Report

Analyst's Ratings for Phaxiam Therapeutics SA (PHXM.PA)

Based on 7 analysts giving stock ratings to Phaxiam Therapeutics SA in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Phaxiam Therapeutics SA. Stock Analysis PHXM.PA

France Health Care Nano Cap Report: 2023 Annual

PHAXIAM Therapeutics SA operates as a biopharmaceutical company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 54 full-time employees. The company went IPO on 2013-05-07. The firm relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.

Key Statistics of Phaxiam Therapeutics SA (PHXM.PA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€0.10€0.12

Today's Open

€0.10

Volume

68.78K

P/E Ratio (TTM)

52 Week Range

€0.03€1.94

Market Cap

1.01M

Avg. Volume

139.91K

Dividend Yield

Financial Metrics & Statements of Phaxiam Therapeutics SA (PHXM.PA)

FAQ's for Phaxiam Therapeutics SA (PHXM.PA)

According to Musaffa’s Shariah screening methodology, Phaxiam Therapeutics SA (PHXM.PA) is currently classified as NOT HALAL as of September 2024. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.